中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study 期刊论文
CHINESE MEDICAL JOURNAL, 2012, 卷号: 125
-
收藏  |  浏览/下载：38/0  |  提交时间：2020/10/26
PHASE-III  GROWTH  METAANALYSIS  PLACEBO  RISK  bevacizumab  metastatic breast cancer  angiogenesis  first-line  Chinese  docetaxel  
Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer 期刊论文
CHINESE MEDICAL JOURNAL, 2010, 卷号: 123
-
收藏  |  浏览/下载：26/0  |  提交时间：2020/10/26
PHASE-III TRIAL  PLUS DOCETAXEL  MULTICENTER  THERAPY  PHOSPHORYLASE  TOLERABILITY  PACLITAXEL  XELODA(R)  SURVIVAL  capecitabine  weekly docetaxel  metastatic breast cancer  anthracycline  elderly  tolerability